<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Genetics and clinical manifestations of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Genetics and clinical manifestations of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Genetics and clinical manifestations of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Deborah P Merke, MD, MS</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lynnette K Nieman, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Benjamin A Raby, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Katya Rubinow, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 10, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Defective conversion of 17-hydroxyprogesterone to 11-deoxycortisol accounts for more than 90 percent of cases of congenital adrenal hyperplasia (CAH) [<a href="#rid1">1-3</a>]. This conversion is mediated by 21-hydroxylase, the enzyme encoded by the <em>CYP21A2</em> gene.</p><p>Patients with "classic" or the most severe form of CAH due to 21-hydroxylase deficiency (21OHD) present during the neonatal period and early infancy with adrenal insufficiency with or without salt-wasting, or as toddlers with virilization. Females have atypical genitalia.</p><p>"Nonclassic," or late-onset 21OHD, presents later in life with signs of androgen excess and without atypical genitalia. Clinical features in childhood may include premature pubarche and accelerated bone age; adolescent and adult females may present with hirsutism, menstrual irregularity, infertility, and acne. Some patients with nonclassic CAH remain asymptomatic.</p><p>The pathophysiology, genetics, and clinical manifestations of CAH due to <em>CYP21A2</em> mutations will be reviewed here. The diagnosis and treatment of classic 21OHD in adults and in children and an overview of nonclassic and unusual forms of CAH are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/145.html" rel="external">"Clinical manifestations and diagnosis of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children"</a> and  <a class="medical medical_review" href="/z/d/html/136.html" rel="external">"Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in adults"</a> and  <a class="medical medical_review" href="/z/d/html/5800.html" rel="external">"Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children"</a> and  <a class="medical medical_review" href="/z/d/html/144.html" rel="external">"Genetics and clinical presentation of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency"</a> and  <a class="medical medical_review" href="/z/d/html/15686.html" rel="external">"Uncommon congenital adrenal hyperplasias"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PREVALENCE</span><span class="headingEndMark"> — </span>The most common cause of congenital adrenal hyperplasia (CAH) worldwide, accounting for &gt;90 percent of cases, is 21-hydroxylase deficiency (21OHD) [<a href="#rid1">1</a>]. Based upon neonatal screening studies that detect classic CAH, 21OHD is one of the more common inherited disorders. Data from approximately 6.5 million newborn infants screened worldwide show an estimate of approximately 1 in 15,000 livebirths [<a href="#rid4">4,5</a>]. Prevalence varies according to race and geographic area. This number varies from as low as 1 in 28,000 in the Chinese population [<a href="#rid6">6</a>], to 1 in 5000 to 23,000 live births in White persons [<a href="#rid7">7,8</a>], to as high as 1 in 280 in the Yupik people in Alaska [<a href="#rid9">9</a>] and 1 in 2100 among people in the French island of La Reunion [<a href="#rid5">5</a>].</p><p>In the United States, the prevalence is lower in African Americans than in White Americans (1 in 42,000 versus 1 in 15,500, respectively) [<a href="#rid10">10</a>].</p><p>Approximately 67 percent of patients with classic CAH are classified as "salt-wasting," while 33 percent of classic patients have the "non-salt-wasting" or "simple virilizing" form, reflecting the degree of aldosterone deficiency [<a href="#rid4">4</a>].</p><p>The nonclassic form of CAH is estimated to be one of the most common autosomal recessive diseases. Among White persons, the prevalence of these forms of the disorder may be as high as 1 in 1000 to 1 in 100 [<a href="#rid11">11,12</a>]. (See  <a class="medical medical_review" href="/z/d/html/144.html" rel="external">"Genetics and clinical presentation of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency", section on 'Prevalence'</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>The defective conversion of 17-hydroxyprogesterone to 11-deoxycortisol in patients with 21-hydroxylase deficiency (21OHD) results in decreased cortisol synthesis and therefore increased corticotropin (ACTH) secretion  (<a class="graphic graphic_figure graphicRef81907" href="/z/d/graphic/81907.html" rel="external">figure 1</a>). The resulting adrenal stimulation leads to increased production of androgens. The severity of disease relates to the degree to which the mutations compromise enzyme activity [<a href="#rid13">13</a>]. (See  <a class="medical medical_review" href="/z/d/html/120.html" rel="external">"Adrenal steroid biosynthesis"</a> and <a class="local">'Genotype versus phenotype'</a> below.)</p><p class="headingAnchor" id="H2402166464"><span class="h1">GENETICS</span><span class="headingEndMark"> — </span>As with the other forms of congenital adrenal hyperplasia (CAH), 21-hydroxylase deficiency (21OHD) is transmitted as an autosomal recessive disorder [<a href="#rid14">14</a>].</p><p>There may be a survival advantage for heterozygote carriers who have a small, but significantly greater, adrenal response to corticotropin (ACTH) than noncarriers [<a href="#rid15">15</a>].</p><p>Humans have two <em>CYP21A</em> genes, a nonfunctional pseudogene (<em>CYP21A1P</em> or <em>CYP21P</em>) and the active gene (<em>CYP21A2</em> or <em>CYP21</em>), both located in a 35-kilobase region of chromosome 6p21.3 within the major human leukocyte antigen (HLA) histocompatibility locus [<a href="#rid16">16-19</a>]. The pseudogene produces a truncated enzyme with no activity because it lacks eight bases from codons 110-112, resulting in a stop codon [<a href="#rid18">18,19</a>].</p><p>The two <em>CYP21A</em> genes are more than 90 percent homologous. This high degree of homology facilitates recombination events during meiosis, with consequent exchanges of segments of DNA between the two genes.</p><p class="bulletIndent1"><span class="glyph">●</span>Unequal crossover exchanges leading to deletions of large segments of the <em>CYP21P</em> gene or a nonfunctioning <em>CYP21P</em>/<em>CYP21</em> fusion gene (macroconversion) account for approximately 20 to 30 percent of <em>CYP21A2</em> mutations described to date [<a href="#rid1">1,7,20</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other hybrid <em>CYP21A1P</em>/<em>CYP21A2</em> gene products have decreased, not absent, enzyme activity. A patient who is heterozygous for this hybrid gene product and a typical large gene deletion may have nonclassic or simple virilizing 21OHD [<a href="#rid21">21,22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CAH-X syndrome, a variant of CAH, results from unequal crossover exchanges between <em>CYP21A2</em> and <em>CYP21A2P</em> and neighboring genes that can occur due to the high recombination rate in the HLA region. The neighboring <em>TNXB</em> gene encodes tenascin-X, an extracellular matrix protein that plays a role in connective tissue and collagen deposition. Hybrid <em>TNXA/TNXB</em> genes lead to complete deletion of the <em>CYP21A2</em> gene. Patients with CAH who carry a <em>TNXA/TNXB</em> gene have features characteristic of hypermobility-type Ehlers-Danlos syndrome, a presentation called CAH-X syndrome [<a href="#rid23">23</a>]. Heterozygosity for a <em>TNXA/TNXB </em>chimera (<em>TNXA/TNXB</em> on one allele) may cause clinical features of a connective tissue dysplasia, while homozygosity (a <em>TNXA/TNXB </em>gene on both alleles) results in a more severe phenotype [<a href="#rid24">24,25</a>]. Approximately 15 percent of patients with CAH have CAH-X syndrome; this prevalence has been similarly reported in cohort studies worldwide including in the United States (278 patients), China (424 patients), and Argentina (337 patients) [<a href="#rid26">26-28</a>]. Clinical manifestations of Ehlers-Danlos syndromes are reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/14920.html" rel="external">"Clinical manifestations and diagnosis of Ehlers-Danlos syndromes"</a>.)</p><p></p><p>Altered regions of the <em>CYP21A1P</em> gene can be transferred to the <em>CYP21A2</em> gene though nonreciprocal gene conversion. This is a process by which a segment of genetic material is transferred to a closely related gene, altering its sequence [<a href="#rid29">29,30</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>These microconversion events represent acquisition of smaller segments of the <em>CYP21A1</em> sequence by the <em>CYP21A1P</em> gene and result in deleterious point mutations that reduce enzyme activity [<a href="#rid3">3,18-20</a>]. They are present in approximately 70 percent of patients with defined genetic abnormalities.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Over 200 pseudogene-independent mutations have been reported in genetic databases, and most of these rare mutations are sporadic [<a href="#rid31">31-33</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Eighteen gene conversion mutations account for nearly all affected alleles in various ethnic groups [<a href="#rid3">3</a>]. The remaining 5 percent of patients with defined abnormalities have one or more of the point mutations thus far identified, most being compound heterozygotes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Approximately 1 to 2 percent of <em>CYP21A2</em> mutations arise de novo [<a href="#rid34">34</a>].</p><p></p><p>Among 130 Brazilian patients, 20 percent did not have a known mutation, suggesting that other mutations occur. A novel missense mutation was subsequently identified in three patients with suggestion of a founder effect [<a href="#rid35">35</a>]. No mutation was detected in the entire coding region of the gene and up to 1 kb of the 5'-flanking promoter region of the gene in one Mexican and three Japanese patients, suggesting that more distant mutations may occur [<a href="#rid36">36,37</a>].</p><p>Genotypically, women with the nonclassic form may be either compound heterozygotes (for example, with a classic mutation on one allele and a nonclassic mutation on the second allele) or homozygous with two nonclassic alleles. Relatives of women with this attenuated form of CAH may have similar biochemical abnormalities but no signs of androgen excess. Women who carry the classic (severe) mutation have an increased risk of giving birth to a child with classic CAH. (See  <a class="medical medical_review" href="/z/d/html/144.html" rel="external">"Genetics and clinical presentation of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency"</a>.)</p><p class="headingAnchor" id="H5"><span class="h2">Genotype versus phenotype</span><span class="headingEndMark"> — </span>It is not always possible to predict the phenotype of these patients from the specific mutation(s) of the <em>CYP21A2</em> gene, but there are general correlations between genotype and phenotype [<a href="#rid3">3,38-51</a>]. With the exception of severe <em>CYP21A2</em> mutations, clinical phenotypes sometimes overlap along a continuum of disease severity. Other genes can modify steroid action, salt balance, or androgen sensitivity and thereby influence the clinical manifestations of CAH [<a href="#rid52">52,53</a>]. Patients with <em>CYP21A2</em> mutations can be divided into groups according to the predicted effect of the mutation on 21-hydroxylase enzymatic activity, as determined by site-directed mutagenesis and expression and in vitro analysis of enzymatic activity [<a href="#rid39">39</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The salt-wasting form of the disorder is most often associated with large deletions or intron 2 mutations that affect splicing and result in no enzyme activity. The correlation between genotype and phenotype for severe mutations (0 to 1 percent activity) is strong, whereas greater phenotypic variability exists for intermediate and less severely affected genotypes [<a href="#rid54">54</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with the simple virilizing form have low but detectable enzyme activity (ie, 1 to 5 percent) that supports sufficient aldosterone and glucocorticoid production. This most commonly results from point mutations leading to nonconservative amino acid substitutions such as Ile172Asp.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Women with the nonclassic form may be either compound heterozygotes (with a classic mutation and a variant allele) or homozygotes with two variant alleles, allowing for 20 to 60 percent of normal enzymatic activity (eg, with point mutations leading to conservative amino acid substitutions such as Val281Leu).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who are compound heterozygotes for two different <em>CYP21A2</em> mutations usually have the phenotype associated with the less severe of the two genetic defects [<a href="#rid55">55</a>]. Heterozygotes may have mild biochemical abnormalities [<a href="#rid15">15,56,57</a>], but no clinically important endocrine disorder.</p><p></p><p class="headingAnchor" id="H2516334923"><span class="h2">Genetic testing</span><span class="headingEndMark"> — </span>The utility of genotype in the management of CAH is uncertain, and genetic testing is not routinely recommended. Genotyping is indicated if the diagnosis remains equivocal following hormonal evaluation or to guide genetic counseling especially in those seeking fertility [<a href="#rid54">54,58</a>]. </p><p>Diagnostic <em>CYP21A2</em> genotyping should only be performed by accredited laboratories. <em>CYP21A2</em> genotyping is error prone due to the presence of the pseudogene and complex gene duplications, deletions, and rearrangements, often resulting in challenging interpretation of results [<a href="#rid59">59</a>]. Parental samples are often needed to accurately determine if disease-causing mutations are on the same or different alleles [<a href="#rid59">59</a>]. Parental genotyping is also needed to determine whether a child's disease-causing mutations are de novo<em> </em>or inherited and assess parental risk of having future affected children. Genetic counseling should accompany <em>CYP21A2</em> genotyping and is important for family planning. (See  <a class="medical medical_review" href="/z/d/html/145.html" rel="external">"Clinical manifestations and diagnosis of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children", section on 'Role of genetic testing'</a>.)</p><p>Individuals carrying the p.Gln318stop (p.Q318X) variant often have duplication of the <em>CYP21A2</em> gene [<a href="#rid60">60</a>]. When this mutation is detected it is important to establish the number of gene copies in order to accurately distinguish between the carrier and disease state [<a href="#rid61">61</a>].</p><p>The nature of the identified mutations (salt-wasting, simple virilizing, or nonclassic) is important because this informs the decision regarding prenatal diagnosis during future pregnancies [<a href="#rid59">59</a>]. When available, in vitro fertilization with preimplantation genetic testing can reduce the risk of having an affected child [<a href="#rid62">62</a>]. (See  <a class="medical medical_review" href="/z/d/html/6783.html" rel="external">"Preimplantation genetic testing", section on 'Patients known to be at increased risk of offspring with a specific medically actionable condition'</a>.)</p><p class="headingAnchor" id="H6"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H2807657022"><span class="h2">Presentation</span><span class="headingEndMark"> — </span>The clinical spectrum of disease ranges from the most severe to mild forms, depending on the degree of 21-hydroxylase deficiency (21OHD) [<a href="#rid54">54</a>]. Three main clinical phenotypes have been described: classic salt-wasting, classic simple virilizing (non-salt-wasting), and nonclassic (late onset):</p><p class="bulletIndent1"><span class="glyph">●</span>Females with the classic form (salt-wasting and simple virilizing) present with atypical genitalia. (See  <a class="medical medical_review" href="/z/d/html/5803.html" rel="external">"Evaluation of the infant with atypical genital appearance (difference of sex development)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Males with the salt-wasting form who are not identified by neonatal screening present with failure to thrive, dehydration, hyponatremia, and hyperkalemia typically at 7 to 14 days of life.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Males with the classic simple virilizing form who are not identified by neonatal screening typically present at two to four years of age with early virilization (pubic hair, growth spurt, adult body odor).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nonclassic or late-onset 21OHD may present as hirsutism and menstrual irregularity in young women, early pubarche or sexual precocity in school-age children, or there may be no symptoms. (See  <a class="medical medical_review" href="/z/d/html/144.html" rel="external">"Genetics and clinical presentation of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency"</a>.)</p><p></p><p class="headingAnchor" id="H7"><span class="h2">Infants/children</span></p><p class="headingAnchor" id="H8"><span class="h3">Atypical genitalia</span><span class="headingEndMark"> — </span>Female infants with classic 21OHD are born with atypical genitalia. Female newborns have clitoral enlargement  (<a class="graphic graphic_picture graphicRef64870" href="/z/d/graphic/64870.html" rel="external">picture 1</a>), labial fusion, and formation of a urogenital sinus caused by the effects of androgen excess on development of the external genitalia in utero. Rarely, genital ambiguity may be so profound that inappropriate sex assignment is made at birth. (See  <a class="medical medical_review" href="/z/d/html/5803.html" rel="external">"Evaluation of the infant with atypical genital appearance (difference of sex development)"</a>.)</p><p>Affected males are normal appearing at birth but may have subtle findings such as hyperpigmentation of the scrotum or an enlarged phallus.</p><p>The surgical management of children born with atypical genitalia is complex. Surgery should be done only in medical centers with substantial experience, and management ideally should be done by a multidisciplinary team that includes specialists in pediatric endocrinology, pediatric surgery, urology, psychosocial services, and genetics [<a href="#rid58">58,63</a>]. This topic is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5807.html" rel="external">"Management of the infant with atypical genital appearance (difference of sex development)", section on 'Clinical approach to 46,XX congenital adrenal hyperplasia'</a>.)</p><p class="headingAnchor" id="H9"><span class="h3">Growth</span><span class="headingEndMark"> — </span>Children with congenital adrenal hyperplasia (CAH) are at risk for early puberty and adult short stature. Exposure to high levels of sex hormones can induce early puberty and premature epiphyseal closure. Excess glucocorticoid exposure secondary to treatment may also suppress growth and contribute to adult short stature.</p><p>Retrospective studies have shown that the final height of treated patients is independent of the degree of control of adrenal androgen concentrations, suggesting that both hyperandrogenism and hypercortisolism play a role in the observed short stature. A meta-analysis of data from 35 studies showed that the mean adult height of patients with classic CAH was 1.4 standard deviations (10 cm) below the population mean [<a href="#rid64">64</a>]. Patients with nonclassic CAH have a more favorable height prognosis but are also at risk for loss of adult height. (See  <a class="medical medical_review" href="/z/d/html/5800.html" rel="external">"Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children", section on 'Growth'</a>.)</p><p class="headingAnchor" id="H10"><span class="h2">Behavior and psychological health</span><span class="headingEndMark"> — </span>Studies of female patients with classic CAH suggest that exposure to excess androgens during prenatal development may influence the brain as evidenced by the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Female patients with classic CAH have more male-typical childhood play than unaffected girls [<a href="#rid65">65,66</a>] and have more interest in male-typical activities and careers [<a href="#rid67">67</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Women with both classic and nonclassic CAH are more likely to self-identify as lesbian or bisexual people compared with women without CAH [<a href="#rid68">68</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adolescent and adult women with CAH may have greater aggressive tendencies than unaffected healthy women [<a href="#rid69">69,70</a>].</p><p></p><p>Swedish registry studies showed that patients with classic CAH have higher prevalence of anxiety, depression, alcohol misuse, suicidality, and adjustment disorders compared with controls [<a href="#rid71">71,72</a>]. In a retrospective cohort study, patients with CAH (n = 605) were found to have increased mortality and depression compared with matched controls (n = 562) [<a href="#rid73">73</a>]. Females with salt-wasting CAH are especially at risk for mental health issues. Alterations in the hypothalamic-pituitary-adrenal axis including endogenous cortisol deficiency and treatment-associated glucocorticoid excess might contribute to the elevated risk of mental health disorders in individuals with CAH.</p><p class="headingAnchor" id="H11"><span class="h2">Cognitive function</span><span class="headingEndMark"> — </span>The effect of 21OHD on cognitive function is uncertain. Some studies suggest that patients with the most severe form of 21OHD and those who have experienced salt-wasting adrenal crises with abnormal electrolytes and/or hypoglycemia as neonates are at risk for cognitive impairment [<a href="#rid74">74</a>]. This was illustrated in a study of 35 Danish women with CAH and healthy age-matched controls undergoing testing with the Wechsler Adult Intelligence Scale (WAIS) [<a href="#rid75">75</a>]. Women with CAH had significantly lower intelligence quotients (IQs) compared with controls (mean full-scale IQ 84.5 versus 99.1 and mean performance IQ 85.7 versus 101.3 in the CAH and control women, respectively). The salt-wasting group had the lowest IQ scores.</p><p>An IQ advantage has also been reported in a number of studies of CAH [<a href="#rid76">76</a>], possibly due to socioeconomic, genetic, or hormonal factors.</p><p>Some data have suggested that girls with CAH develop a more male-typical cognitive pattern (better performance on spatial tasks, worse performance on verbal tasks) [<a href="#rid77">77-79</a>]. However, in a study of 24 women with salt-wasting or simple virilizing 21OHD undergoing detailed cognitive testing, there were no differences in overall IQ, visuospatial processing, or verbal learning and memory [<a href="#rid80">80</a>].</p><p class="headingAnchor" id="H12"><span class="h2">Female reproduction</span><span class="headingEndMark"> — </span>Fertility rates in women with classic forms of 21OHD are low [<a href="#rid81">81</a>]. Possible contributing factors include [<a href="#rid82">82</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Hyperandrogenemia due to inadequate glucocorticoid therapy, thereby resulting in anovulatory cycles [<a href="#rid81">81-83</a>]. The androgen excess is not simply due to corticotropin (ACTH) hypersecretion; other factors include mild hyperresponsiveness of ACTH to corticotropin-releasing hormone stimulation, reduced catalytic activity of the 21-hydroxylase enzyme, and abnormal gonadotropin dynamics with excess ovarian production of progesterone, 17-hydroxyprogesterone, and androgens [<a href="#rid84">84</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Structural factors related to genital malformations or suboptimal surgical reconstruction may leave the vaginal introitus inadequate and may contribute to altered reproductive self-image [<a href="#rid84">84</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fertility rates are related to the severity of the mutation [<a href="#rid85">85</a>]. Pregnancy rates of 60 to 80 percent and 7 to 60 percent of women have been reported in women with classic simple virilizing and classic salt-wasting CAH, respectively [<a href="#rid83">83</a>].</p><p></p><p>In women with classic 21OHD who do conceive, their unaffected female offspring do not have genital virilization, but careful management and an increase in glucocorticoid dose as the pregnancy progresses is indicated [<a href="#rid62">62</a>]. The management of fertility and pregnancy in women with CAH is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/136.html" rel="external">"Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in adults"</a> and  <a class="medical medical_review" href="/z/d/html/136.html" rel="external">"Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in adults", section on 'Pregnancy'</a>.)</p><p>Adrenal rest tumors in the ovary are rare [<a href="#rid86">86</a>], unlike in male patients, who often have testicular adrenal rest tumors. (See  <a class="medical medical_review" href="/z/d/html/136.html" rel="external">"Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in adults"</a>.)</p><p class="headingAnchor" id="H13"><span class="h2">Male reproduction</span><span class="headingEndMark"> — </span>Reproductive function may be impaired in men with 21OHD. Affected boys or young men may have no symptoms or signs of androgen excess. However, they may have testicular masses composed of adrenal tissue.</p><p class="headingAnchor" id="H14"><span class="h3">Testicular adrenal rests</span><span class="headingEndMark"> — </span>Testicular adrenal rest tumors, which are testicular masses composed of adrenal-like tissue, are common in male patients with 21OHD [<a href="#rid87">87-89</a>].</p><p>Confirmation that these tumors resemble adrenal tissue comes from a study of eight adult patients who underwent testis-sparing surgery [<a href="#rid90">90</a>]. Adrenal-specific steroid secretion was documented with preoperative spermatic vein sampling, and expression of adrenal-specific enzymes and ACTH receptors was confirmed in tumor tissue.</p><p>The clinical features of testicular rest tumors include:</p><p class="bulletIndent1"><span class="glyph">●</span>They are usually diagnosed between the ages of 10 and 20 years but may be found as early as age five [<a href="#rid91">91-93</a>]. In one report of 34 boys with classic 21OHD between the ages of 2 and 18 years who were undergoing testicular ultrasonography, eight (24 percent) were diagnosed with testicular adrenal rests; two of the boys were age seven [<a href="#rid93">93</a>]. A similar prevalence was reported in a second report of 19 boys (mean age 5.6 years, range 2 to 10 years) [<a href="#rid94">94</a>]. Inhibin B and anti-müllerian hormone concentrations were lower in patients compared with age-matched controls, suggesting that gonadal dysfunction was also present.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ultrasound studies suggest that the majority of adolescent and adult males with 21OHD have testicular adrenal rests (18 of 21 [86 percent] and 16 of 17 [94 percent] in two reports) [<a href="#rid88">88,89,95</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>They are more common in patients with the salt-wasting form than the simple virilizing form, as the former tend to have poorer control and higher ACTH concentrations [<a href="#rid96">96</a>]. However, a correlation between ACTH levels and tumor growth is not always seen [<a href="#rid87">87,88</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>They are typically bilateral and vary in size from 2 to 40 mm in diameter [<a href="#rid89">89</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>They may lead to obstruction of seminiferous tubules, gonadal dysfunction, and infertility. (See <a class="local">'Infertility'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some, but not all, regress during glucocorticoid therapy [<a href="#rid97">97</a>]. A minority of patients with large adrenal rest tumors eventually requires surgery for pain relief. (See  <a class="medical medical_review" href="/z/d/html/136.html" rel="external">"Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in adults"</a>.)</p><p></p><p>Screening for testicular adrenal rest tumors and adrenal rest management are reviewed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/136.html" rel="external">"Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in adults"</a>.)</p><p class="headingAnchor" id="H15"><span class="h3">Infertility</span><span class="headingEndMark"> — </span>Some men with 21OHD are fertile as adults, but others have evidence of Leydig cell failure or impaired spermatogenesis [<a href="#rid88">88,89,98</a>]. As noted above, testicular adrenal rests may be associated with seminiferous tubule obstruction, gonadal dysfunction, and infertility. (See <a class="local">'Testicular adrenal rests'</a> above.)</p><p>In one study of 17 adolescent and adult men, serum testosterone concentrations were low in 6 men and 7 of 11 men had abnormal semen analyses [<a href="#rid88">88</a>]. In a second report of 30 men, those with adrenal rests in the testes were more likely to be infertile [<a href="#rid87">87</a>].</p><p class="headingAnchor" id="H16"><span class="h2">Epinephrine deficiency</span><span class="headingEndMark"> — </span>Adrenomedullary function is compromised in patients with classic CAH, as illustrated in a study of 38 children with classic 21OHD. Plasma epinephrine and metanephrine concentrations and urinary epinephrine excretion were 40 to 80 percent lower than in healthy individuals [<a href="#rid99">99</a>]. In three patients who underwent bilateral adrenalectomy, the adrenal medulla was poorly formed and the cells contained few vesicles.</p><p>In a second study, the epinephrine response to exercise was significantly reduced in patients with classic 21OHD compared with healthy volunteers [<a href="#rid100">100</a>], and stress doses of <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a> did not improve the response [<a href="#rid101">101</a>]. Thus, 21OHD compromises both the development and subsequent functioning of the adrenomedullary system in severely affected individuals. The combination of cortisol deficiency and epinephrine deficiency puts patients at risk for hypoglycemia with illness or fasting, and impaired adrenomedullary function increases risk of illness in infants with CAH [<a href="#rid102">102,103</a>]. In contrast, adrenomedullary function in response to exercise was found to be normal in five untreated patients with nonclassic CAH [<a href="#rid104">104</a>].</p><p class="headingAnchor" id="H17"><span class="h2">Other findings</span><span class="headingEndMark"> — </span>Other clinical findings that have been described include adrenal incidentalomas, pituitary adenomas, insulin resistance, and hyperleptinemia.</p><p class="bulletIndent1"><span class="glyph">●</span>Although 60 percent of patients with unilateral adrenal incidentalomas and even more of those with bilateral incidentalomas, have exaggerated serum 17-hydroxyprogesterone responses to ACTH stimulation [<a href="#rid1">1</a>], the prevalence of germline <em>CYP21A2</em> mutations is low. However, unilateral and bilateral adrenal incidentalomas were found in 10 of 12 patients with simple virilizing and five of seven patients with late-onset CAH, as well as 9 of 10 heterozygotic siblings [<a href="#rid105">105</a>]. Most tumors had a diameter of less than 2 cm, but three patients had masses more than 5 cm in size. Adrenal masses in children with <em>CYP21A2</em> deficiency are usually benign [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pituitary microadenomas or empty sella may be found, but symptomatic corticotroph tumors have not been reported [<a href="#rid1">1,106</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Insulin resistance has been reported in patients with both classic [<a href="#rid107">107</a>] and nonclassic [<a href="#rid108">108</a>] 21OHD. Hyperandrogenism, glucocorticoid therapy, and epinephrine deficiency have all been implicated as possible risk factors for insulin resistance [<a href="#rid13">13,107,108</a>]. Hyperleptinemia has also been reported [<a href="#rid107">107,109</a>].</p><p></p><p class="headingAnchor" id="H3401764579"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112671.html" rel="external">"Society guideline links: Classic and nonclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency"</a>.)</p><p class="headingAnchor" id="H102065984"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/16935.html" rel="external">"Patient education: Congenital adrenal hyperplasia (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H19"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevalence</strong> – Over 95 percent of cases of congenital adrenal hyperplasia (CAH) are due to 21-hydroxylase deficiency (21OHD) due to <em>CYP21A2</em> mutations. It is one of the most common known autosomal recessive disorders. (See <a class="local">'Prevalence'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genotype versus phenotype</strong> – It is not always possible to predict the phenotype of these patients from the specific mutation(s) of the <em>CYP21A2</em> gene, but there are general correlations between genotype and phenotype. (See <a class="local">'Genotype versus phenotype'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic testing </strong>–<strong> </strong>Genotyping is indicated if the diagnosis remains equivocal following hormonal evaluation or for genetic counseling. Diagnostic <em>CYP21A2</em> genotyping should only be performed by accredited laboratories. Parental genotyping is often needed to accurately determine genotype. Genetic counseling should accompany <em>CYP21A2</em> genotyping and is important for family planning.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – Classic 21OHD results in one of two clinical syndromes: a salt-wasting form and the simple virilizing form. Girls with both forms present as neonates with atypical genitalia. Boys, if not diagnosed by neonatal screening, present as neonates with a salt-wasting adrenal crisis characterized by hyponatremia, hyperkalemia, and failure to thrive (salt-wasting form) or as toddlers with signs of puberty (simple virilizing form). (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Female reproduction</strong> – Reproductive abnormalities are common in females and include structural abnormalities due to androgen excess in utero and anovulatory menstrual cycles. (See <a class="local">'Female reproduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Male reproduction</strong> – In adult men, testicular masses (adrenal rests), Leydig cell dysfunction, and abnormal semen analyses may be seen. (See <a class="local">'Male reproduction'</a> above.)</p><p></p><p class="headingAnchor" id="H2433846217"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The views expressed in this topic are those of the author(s) and do not reflect the official views or policy of the United States Government or its components.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev 2000; 21:245.</a></li><li><a class="nounderline abstract_t">Pang SY, Wallace MA, Hofman L, et al. Worldwide experience in newborn screening for classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Pediatrics 1988; 81:866.</a></li><li><a class="nounderline abstract_t">Speiser PW, White PC. Congenital adrenal hyperplasia. N Engl J Med 2003; 349:776.</a></li><li><a class="nounderline abstract_t">Pang, S, Clark, A. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: Newborn screening and its relationship to the diagnosis and treatment of the disorder. Screening 1993; 2:105.</a></li><li><a class="nounderline abstract_t">Therrell BL. Newborn screening for congenital adrenal hyperplasia. Endocrinol Metab Clin North Am 2001; 30:15.</a></li><li><a class="nounderline abstract_t">Lee HH, Kuo JM, Chao HT, et al. Carrier analysis and prenatal diagnosis of congenital adrenal hyperplasia caused by 21-hydroxylase deficiency in Chinese. J Clin Endocrinol Metab 2000; 85:597.</a></li><li><a class="nounderline abstract_t">New MI, White PC. Genetic disorders of steroid hormone synthesis and metabolism. Baillieres Clin Endocrinol Metab 1995; 9:525.</a></li><li><a class="nounderline abstract_t">Cutfield WS, Webster D. Newborn screening for congenital adrenal hyperplasia in New Zealand. J Pediatr 1995; 126:118.</a></li><li><a class="nounderline abstract_t">Pang S, Murphey W, Levine LS, et al. A pilot newborn screening for congenital adrenal hyperplasia in Alaska. J Clin Endocrinol Metab 1982; 55:413.</a></li><li><a class="nounderline abstract_t">Therrell BL Jr, Berenbaum SA, Manter-Kapanke V, et al. Results of screening 1.9 million Texas newborns for 21-hydroxylase-deficient congenital adrenal hyperplasia. Pediatrics 1998; 101:583.</a></li><li><a class="nounderline abstract_t">Hannah-Shmouni F, Morissette R, Sinaii N, et al. Revisiting the prevalence of nonclassic congenital adrenal hyperplasia in US Ashkenazi Jews and Caucasians. Genet Med 2017; 19:1276.</a></li><li><a class="nounderline abstract_t">New MI. Extensive clinical experience: nonclassical 21-hydroxylase deficiency. J Clin Endocrinol Metab 2006; 91:4205.</a></li><li><a class="nounderline abstract_t">Merke DP, Bornstein SR. Congenital adrenal hyperplasia. Lancet 2005; 365:2125.</a></li><li><a class="nounderline abstract_t">Pignatelli D, Carvalho BL, Palmeiro A, et al. The Complexities in Genotyping of Congenital Adrenal Hyperplasia: 21-Hydroxylase Deficiency. Front Endocrinol (Lausanne) 2019; 10:432.</a></li><li><a class="nounderline abstract_t">Witchel SF, Lee PA, Suda-Hartman M, et al. Evidence for a heterozygote advantage in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 1997; 82:2097.</a></li><li><a class="nounderline abstract_t">Carroll MC, Campbell RD, Porter RR. Mapping of steroid 21-hydroxylase genes adjacent to complement component C4 genes in HLA, the major histocompatibility complex in man. Proc Natl Acad Sci U S A 1985; 82:521.</a></li><li><a class="nounderline abstract_t">White PC, Grossberger D, Onufer BJ, et al. Two genes encoding steroid 21-hydroxylase are located near the genes encoding the fourth component of complement in man. Proc Natl Acad Sci U S A 1985; 82:1089.</a></li><li><a class="nounderline abstract_t">White PC, New MI, Dupont B. Structure of human steroid 21-hydroxylase genes. Proc Natl Acad Sci U S A 1986; 83:5111.</a></li><li><a class="nounderline abstract_t">Higashi Y, Yoshioka H, Yamane M, et al. Complete nucleotide sequence of two steroid 21-hydroxylase genes tandemly arranged in human chromosome: a pseudogene and a genuine gene. Proc Natl Acad Sci U S A 1986; 83:2841.</a></li><li><a class="nounderline abstract_t">Miller WL. Clinical review 54: Genetics, diagnosis, and management of 21-hydroxylase deficiency. J Clin Endocrinol Metab 1994; 78:241.</a></li><li><a class="nounderline abstract_t">L'Allemand D, Tardy V, Grüters A, et al. How a patient homozygous for a 30-kb deletion of the C4-CYP 21 genomic region can have a nonclassic form of 21-hydroxylase deficiency. J Clin Endocrinol Metab 2000; 85:4562.</a></li><li><a class="nounderline abstract_t">Chen W, Xu Z, Sullivan A, et al. Junction site analysis of chimeric CYP21A1P/CYP21A2 genes in 21-hydroxylase deficiency. Clin Chem 2012; 58:421.</a></li><li><a class="nounderline abstract_t">Merke DP, Chen W, Morissette R, et al. Tenascin-X haploinsufficiency associated with Ehlers-Danlos syndrome in patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2013; 98:E379.</a></li><li><a class="nounderline abstract_t">Burch GH, Gong Y, Liu W, et al. Tenascin-X deficiency is associated with Ehlers-Danlos syndrome. Nat Genet 1997; 17:104.</a></li><li><a class="nounderline abstract_t">Chen W, Perritt AF, Morissette R, et al. Ehlers-Danlos Syndrome Caused by Biallelic TNXB Variants in Patients with Congenital Adrenal Hyperplasia. Hum Mutat 2016; 37:893.</a></li><li><a class="nounderline abstract_t">Lao Q, Brookner B, Merke DP. High-Throughput Screening for CYP21A1P-TNXA/TNXB Chimeric Genes Responsible for Ehlers-Danlos Syndrome in Patients with Congenital Adrenal Hyperplasia. J Mol Diagn 2019; 21:924.</a></li><li><a class="nounderline abstract_t">Marino R, Garrido NP, Ramirez P, et al. Ehlers-Danlos Syndrome: Molecular and Clinical Characterization of TNXA/TNXB Chimeras in Congenital Adrenal Hyperplasia. J Clin Endocrinol Metab 2021; 106:e2789.</a></li><li><a class="nounderline abstract_t">Gao Y, Lu L, Yu B, et al. The Prevalence of the Chimeric TNXA/TNXB Gene and Clinical Symptoms of Ehlers-Danlos Syndrome with 21-Hydroxylase Deficiency. J Clin Endocrinol Metab 2020; 105.</a></li><li><a class="nounderline abstract_t">Miller WL. Gene conversions, deletions, and polymorphisms in congenital adrenal hyperplasia. Am J Hum Genet 1988; 42:4.</a></li><li><a class="nounderline abstract_t">Cooper DN, Ball EV, Krawczak M. The human gene mutation database. Nucleic Acids Res 1998; 26:285.</a></li><li class="breakAll">The Human Gene Mutation Database. Available at: https://www.hgmd.cf.ac.uk/ac/index.php (Accessed on March 09, 2023).</li><li class="breakAll">CYP21A2 allele nomenclature. Available at: https://www.pharmvar.org/gene/CYP21A2 (Accessed on March 09, 2023).</li><li class="breakAll">ClinVar archive of reported human genetic variations. Available at: https://www.ncbi.nlm.nih.gov/clinvar/ (Accessed on March 09, 2023).</li><li><a class="nounderline abstract_t">Claahsen-van der Grinten HL, Speiser PW, Ahmed SF, et al. Congenital Adrenal Hyperplasia-Current Insights in Pathophysiology, Diagnostics, and Management. Endocr Rev 2022; 43:91.</a></li><li><a class="nounderline abstract_t">Billerbeck AE, Mendonca BB, Pinto EM, et al. Three novel mutations in CYP21 gene in Brazilian patients with the classical form of 21-hydroxylase deficiency due to a founder effect. J Clin Endocrinol Metab 2002; 87:4314.</a></li><li><a class="nounderline abstract_t">Nimkarn S, Cerame BI, Wei JQ, et al. Congenital adrenal hyperplasia (21-hydroxylase deficiency) without demonstrable genetic mutations. J Clin Endocrinol Metab 1999; 84:378.</a></li><li><a class="nounderline abstract_t">Koyama S, Toyoura T, Saisho S, et al. Genetic analysis of Japanese patients with 21-hydroxylase deficiency: identification of a patient with a new mutation of a homozygous deletion of adenine at codon 246 and patients without demonstrable mutations within the structural gene for CYP21. J Clin Endocrinol Metab 2002; 87:2668.</a></li><li><a class="nounderline abstract_t">Ferenczi A, Garami M, Kiss E, et al. Screening for mutations of 21-hydroxylase gene in Hungarian patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab 1999; 84:2369.</a></li><li><a class="nounderline abstract_t">Speiser PW, Dupont J, Zhu D, et al. Disease expression and molecular genotype in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Invest 1992; 90:584.</a></li><li><a class="nounderline abstract_t">Wedell A, Thilén A, Ritzén EM, et al. Mutational spectrum of the steroid 21-hydroxylase gene in Sweden: implications for genetic diagnosis and association with disease manifestation. J Clin Endocrinol Metab 1994; 78:1145.</a></li><li><a class="nounderline abstract_t">Wilson RC, Mercado AB, Cheng KC, New MI. Steroid 21-hydroxylase deficiency: genotype may not predict phenotype. J Clin Endocrinol Metab 1995; 80:2322.</a></li><li><a class="nounderline abstract_t">Jääskeläinen J, Levo A, Voutilainen R, Partanen J. Population-wide evaluation of disease manifestation in relation to molecular genotype in steroid 21-hydroxylase (CYP21) deficiency: good correlation in a well defined population. J Clin Endocrinol Metab 1997; 82:3293.</a></li><li><a class="nounderline abstract_t">Finkielstain GP, Chen W, Mehta SP, et al. Comprehensive genetic analysis of 182 unrelated families with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 2011; 96:E161.</a></li><li><a class="nounderline abstract_t">Higashi Y, Hiromasa T, Tanae A, et al. Effects of individual mutations in the P-450(C21) pseudogene on the P-450(C21) activity and their distribution in the patient genomes of congenital steroid 21-hydroxylase deficiency. J Biochem 1991; 109:638.</a></li><li><a class="nounderline abstract_t">Mornet E, Crété P, Kuttenn F, et al. Distribution of deletions and seven point mutations on CYP21B genes in three clinical forms of steroid 21-hydroxylase deficiency. Am J Hum Genet 1991; 48:79.</a></li><li><a class="nounderline abstract_t">Owerbach D, Ballard AL, Draznin MB. Salt-wasting congenital adrenal hyperplasia: detection and characterization of mutations in the steroid 21-hydroxylase gene, CYP21, using the polymerase chain reaction. J Clin Endocrinol Metab 1992; 74:553.</a></li><li><a class="nounderline abstract_t">Dardis A, Bergada I, Bergada C, et al. Mutations of the steroid 21-hydroxylase gene in an Argentinian population of 36 patients with classical congenital adrenal hyperplasia. J Pediatr Endocrinol Metab 1997; 10:55.</a></li><li><a class="nounderline abstract_t">Krone N, Braun A, Roscher AA, et al. Predicting phenotype in steroid 21-hydroxylase deficiency? Comprehensive genotyping in 155 unrelated, well defined patients from southern Germany. J Clin Endocrinol Metab 2000; 85:1059.</a></li><li><a class="nounderline abstract_t">Deneux C, Tardy V, Dib A, et al. Phenotype-genotype correlation in 56 women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 2001; 86:207.</a></li><li><a class="nounderline abstract_t">Balsamo A, Cicognani A, Baldazzi L, et al. CYP21 genotype, adult height, and pubertal development in 55 patients treated for 21-hydroxylase deficiency. J Clin Endocrinol Metab 2003; 88:5680.</a></li><li><a class="nounderline abstract_t">Grigorescu Sido A, Weber MM, Grigorescu Sido P, et al. 21-Hydroxylase and 11beta-hydroxylase mutations in Romanian patients with classic congenital adrenal hyperplasia. J Clin Endocrinol Metab 2005; 90:5769.</a></li><li><a class="nounderline abstract_t">Gomes LG, Huang N, Agrawal V, et al. Extraadrenal 21-hydroxylation by CYP2C19 and CYP3A4: effect on 21-hydroxylase deficiency. J Clin Endocrinol Metab 2009; 94:89.</a></li><li><a class="nounderline abstract_t">Kaupert LC, Lemos-Marini SH, De Mello MP, et al. The effect of fetal androgen metabolism-related gene variants on external genitalia virilization in congenital adrenal hyperplasia. Clin Genet 2013; 84:482.</a></li><li><a class="nounderline abstract_t">Merke DP, Auchus RJ. Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency. N Engl J Med 2020; 383:1248.</a></li><li><a class="nounderline abstract_t">Lajić S, Clauin S, Robins T, et al. Novel mutations in CYP21 detected in individuals with hyperandrogenism. J Clin Endocrinol Metab 2002; 87:2824.</a></li><li><a class="nounderline abstract_t">Gutai JP, Kowarski AA, Migeon CJ. The detection of the heterozygous carrier for congenital virilizing adrenal hyperplasia. J Pediatr 1977; 90:924.</a></li><li><a class="nounderline abstract_t">Charmandari E, Merke DP, Negro PJ, et al. Endocrinologic and psychologic evaluation of 21-hydroxylase deficiency carriers and matched normal subjects: evidence for physical and/or psychologic vulnerability to stress. J Clin Endocrinol Metab 2004; 89:2228.</a></li><li><a class="nounderline abstract_t">Speiser PW, Azziz R, Baskin LS, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010; 95:4133.</a></li><li><a class="nounderline abstract_t">Baumgartner-Parzer S, Witsch-Baumgartner M, Hoeppner W. EMQN best practice guidelines for molecular genetic testing and reporting of 21-hydroxylase deficiency. Eur J Hum Genet 2020; 28:1341.</a></li><li><a class="nounderline abstract_t">Kharrat M, Riahi A, Maazoul F, et al. Detection of a frequent duplicated CYP21A2 gene carrying a Q318X mutation in a general population with quantitative PCR methods. Diagn Mol Pathol 2011; 20:123.</a></li><li><a class="nounderline abstract_t">Concolino P, Costella A. Congenital Adrenal Hyperplasia (CAH) due to 21-Hydroxylase Deficiency: A Comprehensive Focus on 233 Pathogenic Variants of CYP21A2 Gene. Mol Diagn Ther 2018; 22:261.</a></li><li><a class="nounderline abstract_t">Maher JY, Gomez-Lobo V, Merke DP. The management of congenital adrenal hyperplasia during preconception, pregnancy, and postpartum. Rev Endocr Metab Disord 2023; 24:71.</a></li><li><a class="nounderline abstract_t">Joint LWPES/ESPE CAH Working Group.. Consensus statement on 21-hydroxylase deficiency from the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology. J Clin Endocrinol Metab 2002; 87:4048.</a></li><li><a class="nounderline abstract_t">Muthusamy K, Elamin MB, Smushkin G, et al. Clinical review: Adult height in patients with congenital adrenal hyperplasia: a systematic review and metaanalysis. J Clin Endocrinol Metab 2010; 95:4161.</a></li><li><a class="nounderline abstract_t">Berenbaum, SA, Snyder, E. Early hormonal influences on childhood sex-typed activity and playmate preferences: implications for the development of sexual orientation. Dev Psychol 1995; 31:31.</a></li><li><a class="nounderline abstract_t">Dittmann RW, Kappes MH, Kappes ME, et al. Congenital adrenal hyperplasia. I: Gender-related behavior and attitudes in female patients and sisters. Psychoneuroendocrinology 1990; 15:401.</a></li><li><a class="nounderline abstract_t">Berenbaum SA. Effects of early androgens on sex-typed activities and interests in adolescents with congenital adrenal hyperplasia. Horm Behav 1999; 35:102.</a></li><li><a class="nounderline abstract_t">Meyer-Bahlburg HF, Dolezal C, Baker SW, New MI. Sexual orientation in women with classical or non-classical congenital adrenal hyperplasia as a function of degree of prenatal androgen excess. Arch Sex Behav 2008; 37:85.</a></li><li><a class="nounderline abstract_t">Berenbaum SA, Resnick SM. Early androgen effects on aggression in children and adults with congenital adrenal hyperplasia. Psychoneuroendocrinology 1997; 22:505.</a></li><li><a class="nounderline abstract_t">Mathews GA, Fane BA, Conway GS, et al. Personality and congenital adrenal hyperplasia: possible effects of prenatal androgen exposure. Horm Behav 2009; 55:285.</a></li><li><a class="nounderline abstract_t">Engberg H, Butwicka A, Nordenström A, et al. Congenital adrenal hyperplasia and risk for psychiatric disorders in girls and women born between 1915 and 2010: A total population study. Psychoneuroendocrinology 2015; 60:195.</a></li><li><a class="nounderline abstract_t">Falhammar H, Butwicka A, Landén M, et al. Increased psychiatric morbidity in men with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 2014; 99:E554.</a></li><li><a class="nounderline abstract_t">Jenkins-Jones S, Parviainen L, Porter J, et al. Poor compliance and increased mortality, depression and healthcare costs in patients with congenital adrenal hyperplasia. Eur J Endocrinol 2018; 178:309.</a></li><li><a class="nounderline abstract_t">Berenbaum SA. Cognitive function in congenital adrenal hyperplasia. Endocrinol Metab Clin North Am 2001; 30:173.</a></li><li><a class="nounderline abstract_t">Johannsen TH, Ripa CP, Reinisch JM, et al. Impaired cognitive function in women with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2006; 91:1376.</a></li><li><a class="nounderline abstract_t">Nass R, Baker S. Androgen effects on cognition: congenital adrenal hyperplasia. Psychoneuroendocrinology 1991; 16:189.</a></li><li><a class="nounderline abstract_t">Helleday J, Bartfai A, Ritzén EM, Forsman M. General intelligence and cognitive profile in women with congenital adrenal hyperplasia (CAH). Psychoneuroendocrinology 1994; 19:343.</a></li><li><a class="nounderline abstract_t">Kelso WM, Nicholls ME, Warne GL, Zacharin M. Cerebral lateralization and cognitive functioning in patients with congenital adrenal hyperplasia. Neuropsychology 2000; 14:370.</a></li><li><a class="nounderline abstract_t">Mueller SC, Temple V, Oh E, et al. Early androgen exposure modulates spatial cognition in congenital adrenal hyperplasia (CAH). Psychoneuroendocrinology 2008; 33:973.</a></li><li><a class="nounderline abstract_t">Malouf MA, Migeon CJ, Carson KA, et al. Cognitive outcome in adult women affected by congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Horm Res 2006; 65:142.</a></li><li><a class="nounderline abstract_t">Mulaikal RM, Migeon CJ, Rock JA. Fertility rates in female patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. N Engl J Med 1987; 316:178.</a></li><li><a class="nounderline abstract_t">Meyer-Bahlburg HF. What causes low rates of child-bearing in congenital adrenal hyperplasia? J Clin Endocrinol Metab 1999; 84:1844.</a></li><li><a class="nounderline abstract_t">Stikkelbroeck NM, Hermus AR, Braat DD, Otten BJ. Fertility in women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Obstet Gynecol Surv 2003; 58:275.</a></li><li><a class="nounderline abstract_t">Hagenfeldt K, Janson PO, Holmdahl G, et al. Fertility and pregnancy outcome in women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Hum Reprod 2008; 23:1607.</a></li><li><a class="nounderline abstract_t">Nordenskjöld A, Holmdahl G, Frisén L, et al. Type of mutation and surgical procedure affect long-term quality of life for women with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2008; 93:380.</a></li><li><a class="nounderline abstract_t">Stikkelbroeck NM, Hermus AR, Schouten D, et al. Prevalence of ovarian adrenal rest tumours and polycystic ovaries in females with congenital adrenal hyperplasia: results of ultrasonography and MR imaging. Eur Radiol 2004; 14:1802.</a></li><li><a class="nounderline abstract_t">Cabrera MS, Vogiatzi MG, New MI. Long term outcome in adult males with classic congenital adrenal hyperplasia. J Clin Endocrinol Metab 2001; 86:3070.</a></li><li><a class="nounderline abstract_t">Stikkelbroeck NM, Otten BJ, Pasic A, et al. High prevalence of testicular adrenal rest tumors, impaired spermatogenesis, and Leydig cell failure in adolescent and adult males with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2001; 86:5721.</a></li><li><a class="nounderline abstract_t">Stikkelbroeck NM, Suliman HM, Otten BJ, et al. Testicular adrenal rest tumours in postpubertal males with congenital adrenal hyperplasia: sonographic and MR features. Eur Radiol 2003; 13:1597.</a></li><li><a class="nounderline abstract_t">Claahsen-van der Grinten HL, Otten BJ, Sweep FC, et al. Testicular tumors in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency show functional features of adrenocortical tissue. J Clin Endocrinol Metab 2007; 92:3674.</a></li><li><a class="nounderline abstract_t">Vanzulli A, DelMaschio A, Paesano P, et al. Testicular masses in association with adrenogenital syndrome: US findings. Radiology 1992; 183:425.</a></li><li><a class="nounderline abstract_t">Avila NA, Shawker TS, Jones JV, et al. Testicular adrenal rest tissue in congenital adrenal hyperplasia: serial sonographic and clinical findings. AJR Am J Roentgenol 1999; 172:1235.</a></li><li><a class="nounderline abstract_t">Claahsen-van der Grinten HL, Sweep FC, Blickman JG, et al. Prevalence of testicular adrenal rest tumours in male children with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Eur J Endocrinol 2007; 157:339.</a></li><li><a class="nounderline abstract_t">Martinez-Aguayo A, Rocha A, Rojas N, et al. Testicular adrenal rest tumors and Leydig and Sertoli cell function in boys with classical congenital adrenal hyperplasia. J Clin Endocrinol Metab 2007; 92:4583.</a></li><li><a class="nounderline abstract_t">Falhammar H, Nyström HF, Ekström U, et al. Fertility, sexuality and testicular adrenal rest tumors in adult males with congenital adrenal hyperplasia. Eur J Endocrinol 2012; 166:441.</a></li><li><a class="nounderline abstract_t">Stikkelbroeck NM, Hermus AR, Suliman HM, et al. Asymptomatic testicular adrenal rest tumours in adolescent and adult males with congenital adrenal hyperplasia: basal and follow-up investigation after 2.6 years. J Pediatr Endocrinol Metab 2004; 17:645.</a></li><li><a class="nounderline abstract_t">Claahsen-van der Grinten HL, Stikkelbroeck N, Falhammar H, Reisch N. MANAGEMENT OF ENDOCRINE DISEASE: Gonadal dysfunction in congenital adrenal hyperplasia. Eur J Endocrinol 2021; 184:R85.</a></li><li><a class="nounderline abstract_t">Newfield RS, New MI. 21-hydroxylase deficiency. Ann N Y Acad Sci 1997; 816:219.</a></li><li><a class="nounderline abstract_t">Merke DP, Chrousos GP, Eisenhofer G, et al. Adrenomedullary dysplasia and hypofunction in patients with classic 21-hydroxylase deficiency. N Engl J Med 2000; 343:1362.</a></li><li><a class="nounderline abstract_t">Weise M, Mehlinger SL, Drinkard B, et al. Patients with classic congenital adrenal hyperplasia have decreased epinephrine reserve and defective glucose elevation in response to high-intensity exercise. J Clin Endocrinol Metab 2004; 89:591.</a></li><li><a class="nounderline abstract_t">Weise M, Drinkard B, Mehlinger SL, et al. Stress dose of hydrocortisone is not beneficial in patients with classic congenital adrenal hyperplasia undergoing short-term, high-intensity exercise. J Clin Endocrinol Metab 2004; 89:3679.</a></li><li><a class="nounderline abstract_t">El-Maouche D, Hargreaves CJ, Sinaii N, et al. Longitudinal Assessment of Illnesses, Stress Dosing, and Illness Sequelae in Patients With Congenital Adrenal Hyperplasia. J Clin Endocrinol Metab 2018; 103:2336.</a></li><li><a class="nounderline abstract_t">Ritchie LD, Harrington LT, MacGregor AR, Vandenburg MJ. Nifedipine as low-dose monotherapy for essential hypertension: a primary care study. Cardiovasc Drugs Ther 1989; 3 Suppl 1:341.</a></li><li><a class="nounderline abstract_t">Verma S, Green-Golan L, VanRyzin C, et al. Adrenomedullary function in patients with nonclassic congenital adrenal hyperplasia. Horm Metab Res 2010; 42:607.</a></li><li><a class="nounderline abstract_t">Jaresch S, Kornely E, Kley HK, Schlaghecke R. Adrenal incidentaloma and patients with homozygous or heterozygous congenital adrenal hyperplasia. J Clin Endocrinol Metab 1992; 74:685.</a></li><li><a class="nounderline abstract_t">Charmandari E, Chrousos GP, Merke DP. Adrenocorticotropin hypersecretion and pituitary microadenoma following bilateral adrenalectomy in a patient with classic 21-hydroxylase deficiency. J Pediatr Endocrinol Metab 2005; 18:97.</a></li><li><a class="nounderline abstract_t">Charmandari E, Weise M, Bornstein SR, et al. Children with classic congenital adrenal hyperplasia have elevated serum leptin concentrations and insulin resistance: potential clinical implications. J Clin Endocrinol Metab 2002; 87:2114.</a></li><li><a class="nounderline abstract_t">Speiser PW, Serrat J, New MI, Gertner JM. Insulin insensitivity in adrenal hyperplasia due to nonclassical steroid 21-hydroxylase deficiency. J Clin Endocrinol Metab 1992; 75:1421.</a></li><li><a class="nounderline abstract_t">Riepe FG, Krone N, Krüger SN, et al. Absence of exercise-induced leptin suppression associated with insufficient epinephrine reserve in patients with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Exp Clin Endocrinol Diabetes 2006; 114:105.</a></li></ol></div><div id="topicVersionRevision">Topic 149 Version 21.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10857554" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Congenital adrenal hyperplasia due to 21-hydroxylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3259306" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Worldwide experience in newborn screening for classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12930931" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Congenital adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: Newborn screening and its relationship to the diagnosis and treatment of the disorder</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11344933" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Newborn screening for congenital adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10690861" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Carrier analysis and prenatal diagnosis of congenital adrenal hyperplasia caused by 21-hydroxylase deficiency in Chinese.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7575331" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Genetic disorders of steroid hormone synthesis and metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7815200" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Newborn screening for congenital adrenal hyperplasia in New Zealand.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7096533" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : A pilot newborn screening for congenital adrenal hyperplasia in Alaska.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9521938" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Results of screening 1.9 million Texas newborns for 21-hydroxylase-deficient congenital adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28541281" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Revisiting the prevalence of nonclassic congenital adrenal hyperplasia in US Ashkenazi Jews and Caucasians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16912124" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Extensive clinical experience: nonclassical 21-hydroxylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15964450" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Congenital adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31333583" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The Complexities in Genotyping of Congenital Adrenal Hyperplasia: 21-Hydroxylase Deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9215278" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Evidence for a heterozygote advantage in congenital adrenal hyperplasia due to 21-hydroxylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3871526" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Mapping of steroid 21-hydroxylase genes adjacent to complement component C4 genes in HLA, the major histocompatibility complex in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2983330" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Two genes encoding steroid 21-hydroxylase are located near the genes encoding the fourth component of complement in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3487786" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Structure of human steroid 21-hydroxylase genes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3486422" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Complete nucleotide sequence of two steroid 21-hydroxylase genes tandemly arranged in human chromosome: a pseudogene and a genuine gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8106606" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Clinical review 54: Genetics, diagnosis, and management of 21-hydroxylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11134109" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : How a patient homozygous for a 30-kb deletion of the C4-CYP 21 genomic region can have a nonclassic form of 21-hydroxylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22156666" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Junction site analysis of chimeric CYP21A1P/CYP21A2 genes in 21-hydroxylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23284009" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Tenascin-X haploinsufficiency associated with Ehlers-Danlos syndrome in patients with congenital adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9288108" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Tenascin-X deficiency is associated with Ehlers-Danlos syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27297501" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Ehlers-Danlos Syndrome Caused by Biallelic TNXB Variants in Patients with Congenital Adrenal Hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31229653" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : High-Throughput Screening for CYP21A1P-TNXA/TNXB Chimeric Genes Responsible for Ehlers-Danlos Syndrome in Patients with Congenital Adrenal Hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33482002" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Ehlers-Danlos Syndrome: Molecular and Clinical Characterization of TNXA/TNXB Chimeras in Congenital Adrenal Hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32291442" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The Prevalence of the Chimeric TNXA/TNXB Gene and Clinical Symptoms of Ehlers-Danlos Syndrome with 21-Hydroxylase Deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3276177" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Gene conversions, deletions, and polymorphisms in congenital adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9399854" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The human gene mutation database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9399854" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The human gene mutation database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9399854" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The human gene mutation database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9399854" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The human gene mutation database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33961029" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Congenital Adrenal Hyperplasia-Current Insights in Pathophysiology, Diagnostics, and Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12213891" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Three novel mutations in CYP21 gene in Brazilian patients with the classical form of 21-hydroxylase deficiency due to a founder effect.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9920112" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Congenital adrenal hyperplasia (21-hydroxylase deficiency) without demonstrable genetic mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12050231" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Genetic analysis of Japanese patients with 21-hydroxylase deficiency: identification of a patient with a new mutation of a homozygous deletion of adenine at codon 246 and patients without demonstrable mutations within the structural gene for CYP21.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10404805" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Screening for mutations of 21-hydroxylase gene in Hungarian patients with congenital adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1644925" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Disease expression and molecular genotype in congenital adrenal hyperplasia due to 21-hydroxylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8175971" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Mutational spectrum of the steroid 21-hydroxylase gene in Sweden: implications for genetic diagnosis and association with disease manifestation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7629224" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Steroid 21-hydroxylase deficiency: genotype may not predict phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9329356" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Population-wide evaluation of disease manifestation in relation to molecular genotype in steroid 21-hydroxylase (CYP21) deficiency: good correlation in a well defined population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20926536" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Comprehensive genetic analysis of 182 unrelated families with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1869518" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Effects of individual mutations in the P-450(C21) pseudogene on the P-450(C21) activity and their distribution in the patient genomes of congenital steroid 21-hydroxylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1985465" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Distribution of deletions and seven point mutations on CYP21B genes in three clinical forms of steroid 21-hydroxylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1740489" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Salt-wasting congenital adrenal hyperplasia: detection and characterization of mutations in the steroid 21-hydroxylase gene, CYP21, using the polymerase chain reaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9364343" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Mutations of the steroid 21-hydroxylase gene in an Argentinian population of 36 patients with classical congenital adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10720040" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Predicting phenotype in steroid 21-hydroxylase deficiency? Comprehensive genotyping in 155 unrelated, well defined patients from southern Germany.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11232002" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Phenotype-genotype correlation in 56 women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14671153" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : CYP21 genotype, adult height, and pubertal development in 55 patients treated for 21-hydroxylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16046588" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : 21-Hydroxylase and 11beta-hydroxylase mutations in Romanian patients with classic congenital adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18957504" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Extraadrenal 21-hydroxylation by CYP2C19 and CYP3A4: effect on 21-hydroxylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22978668" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The effect of fetal androgen metabolism-related gene variants on external genitalia virilization in congenital adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32966723" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12050257" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Novel mutations in CYP21 detected in individuals with hyperandrogenism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/192874" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The detection of the heterozygous carrier for congenital virilizing adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15126546" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Endocrinologic and psychologic evaluation of 21-hydroxylase deficiency carriers and matched normal subjects: evidence for physical and/or psychologic vulnerability to stress.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20823466" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32616876" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : EMQN best practice guidelines for molecular genetic testing and reporting of 21-hydroxylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21532487" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Detection of a frequent duplicated CYP21A2 gene carrying a Q318X mutation in a general population with quantitative PCR methods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29450859" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Congenital Adrenal Hyperplasia (CAH) due to 21-Hydroxylase Deficiency: A Comprehensive Focus on 233 Pathogenic Variants of CYP21A2 Gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36399318" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : The management of congenital adrenal hyperplasia during preconception, pregnancy, and postpartum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12213842" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Consensus statement on 21-hydroxylase deficiency from the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20823467" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Clinical review: Adult height in patients with congenital adrenal hyperplasia: a systematic review and metaanalysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Early hormonal influences on childhood sex-typed activity and playmate preferences: implications for the development of sexual orientation</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2101963" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Congenital adrenal hyperplasia. I: Gender-related behavior and attitudes in female patients and sisters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10049608" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Effects of early androgens on sex-typed activities and interests in adolescents with congenital adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18157628" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Sexual orientation in women with classical or non-classical congenital adrenal hyperplasia as a function of degree of prenatal androgen excess.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9373884" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Early androgen effects on aggression in children and adults with congenital adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19100266" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Personality and congenital adrenal hyperplasia: possible effects of prenatal androgen exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26184920" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Congenital adrenal hyperplasia and risk for psychiatric disorders in girls and women born between 1915 and 2010: A total population study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24302749" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Increased psychiatric morbidity in men with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29371334" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Poor compliance and increased mortality, depression and healthcare costs in patients with congenital adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11344935" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Cognitive function in congenital adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16449336" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Impaired cognitive function in women with congenital adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1961839" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Androgen effects on cognition: congenital adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8047639" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : General intelligence and cognitive profile in women with congenital adrenal hyperplasia (CAH).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10928740" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Cerebral lateralization and cognitive functioning in patients with congenital adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18675711" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Early androgen exposure modulates spatial cognition in congenital adrenal hyperplasia (CAH).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16508325" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Cognitive outcome in adult women affected by congenital adrenal hyperplasia due to 21-hydroxylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3491959" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Fertility rates in female patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10372672" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : What causes low rates of child-bearing in congenital adrenal hyperplasia?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12665708" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Fertility in women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18420648" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Fertility and pregnancy outcome in women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18029470" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Type of mutation and surgical procedure affect long-term quality of life for women with congenital adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15322809" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Prevalence of ovarian adrenal rest tumours and polycystic ovaries in females with congenital adrenal hyperplasia: results of ultrasonography and MR imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11443169" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Long term outcome in adult males with classic congenital adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11739428" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : High prevalence of testicular adrenal rest tumors, impaired spermatogenesis, and Leydig cell failure in adolescent and adult males with congenital adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12835972" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Testicular adrenal rest tumours in postpubertal males with congenital adrenal hyperplasia: sonographic and MR features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17595257" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Testicular tumors in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency show functional features of adrenocortical tissue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1561344" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Testicular masses in association with adrenogenital syndrome: US findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10227495" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Testicular adrenal rest tissue in congenital adrenal hyperplasia: serial sonographic and clinical findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17766717" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Prevalence of testicular adrenal rest tumours in male children with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17895312" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Testicular adrenal rest tumors and Leydig and Sertoli cell function in boys with classical congenital adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22157069" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Fertility, sexuality and testicular adrenal rest tumors in adult males with congenital adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15198296" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Asymptomatic testicular adrenal rest tumours in adolescent and adult males with congenital adrenal hyperplasia: basal and follow-up investigation after 2.6 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33320831" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : MANAGEMENT OF ENDOCRINE DISEASE: Gonadal dysfunction in congenital adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9238271" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : 21-hydroxylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11070100" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Adrenomedullary dysplasia and hypofunction in patients with classic 21-hydroxylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14764767" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Patients with classic congenital adrenal hyperplasia have decreased epinephrine reserve and defective glucose elevation in response to high-intensity exercise.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15292287" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Stress dose of hydrocortisone is not beneficial in patients with classic congenital adrenal hyperplasia undergoing short-term, high-intensity exercise.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29584889" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Longitudinal Assessment of Illnesses, Stress Dosing, and Illness Sequelae in Patients With Congenital Adrenal Hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2487805" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Nifedipine as low-dose monotherapy for essential hypertension: a primary care study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20446239" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Adrenomedullary function in patients with nonclassic congenital adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1311000" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Adrenal incidentaloma and patients with homozygous or heterozygous congenital adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15679075" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Adrenocorticotropin hypersecretion and pituitary microadenoma following bilateral adrenalectomy in a patient with classic 21-hydroxylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11994350" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Children with classic congenital adrenal hyperplasia have elevated serum leptin concentrations and insulin resistance: potential clinical implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1464643" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Insulin insensitivity in adrenal hyperplasia due to nonclassical steroid 21-hydroxylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16636975" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Absence of exercise-induced leptin suppression associated with insufficient epinephrine reserve in patients with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
